Rigel Pharmaceuticals Stock Fundamentals
| RIGL Stock | USD 0.97 0.01 1.02% |
Rigel Pharmaceuticals fundamentals help investors to digest information that contributes to Rigel Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Rigel Stock. The fundamental analysis module provides a way to measure Rigel Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rigel Pharmaceuticals stock.
At this time, Rigel Pharmaceuticals' Selling General Administrative is quite stable compared to the past year. Non Operating Income Net Other is expected to rise to about 936.5 K this year, although the value of Operating Income will most likely fall to (21.5 M). Rigel | Select Account or Indicator |
Rigel Pharmaceuticals Company Return On Equity Analysis
Rigel Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Rigel Pharmaceuticals Return On Equity | -6.99 |
Most of Rigel Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rigel Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Rigel Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Rigel Pharmaceuticals has a Return On Equity of -6.9905. This is 70.84% lower than that of the Biotechnology sector and 80.83% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Rigel Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Rigel Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Rigel Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Rigel Pharmaceuticals competition to find correlations between indicators driving Rigel Pharmaceuticals's intrinsic value. More Info.Rigel Pharmaceuticals is rated fourth in return on equity category among its peers. It is currently regarded as top stock in return on asset category among its peers . At this time, Rigel Pharmaceuticals' Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Rigel Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Rigel Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rigel Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rigel Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Rigel Pharmaceuticals by comparing valuation metrics of similar companies.Rigel Pharmaceuticals is currently under evaluation in return on equity category among its peers.
Rigel Fundamentals
| Return On Equity | -6.99 | ||||
| Return On Asset | -0.0791 | ||||
| Profit Margin | (0.17) % | ||||
| Operating Margin | (0.24) % | ||||
| Current Valuation | 222.88 M | ||||
| Shares Outstanding | 175.41 M | ||||
| Shares Owned By Insiders | 2.10 % | ||||
| Shares Owned By Institutions | 63.83 % | ||||
| Number Of Shares Shorted | 5.64 M | ||||
| Price To Earning | (5.63) X | ||||
| Price To Book | 31.64 X | ||||
| Price To Sales | 1.82 X | ||||
| Revenue | 116.88 M | ||||
| Gross Profit | 53.72 M | ||||
| EBITDA | (16.98 M) | ||||
| Net Income | (25.09 M) | ||||
| Cash And Equivalents | 81.64 M | ||||
| Cash Per Share | 0.47 X | ||||
| Total Debt | 60.58 M | ||||
| Current Ratio | 2.34 X | ||||
| Book Value Per Share | (0.18) X | ||||
| Cash Flow From Operations | (5.74 M) | ||||
| Short Ratio | 3.92 X | ||||
| Earnings Per Share | (0.11) X | ||||
| Price To Earnings To Growth | (0.10) X | ||||
| Target Price | 4.53 | ||||
| Number Of Employees | 147 | ||||
| Beta | 1.06 | ||||
| Market Capitalization | 170.95 M | ||||
| Total Asset | 117.22 M | ||||
| Retained Earnings | (1.41 B) | ||||
| Working Capital | 46 M | ||||
| Current Asset | 129.02 M | ||||
| Current Liabilities | 33.8 M | ||||
| Net Asset | 117.22 M |
About Rigel Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rigel Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rigel Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rigel Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 17 M | 17.9 M | |
| Total Revenue | 116.9 M | 122.7 M | |
| Cost Of Revenue | 7.1 M | 6.8 M | |
| Stock Based Compensation To Revenue | 0.08 | 0.07 | |
| Sales General And Administrative To Revenue | 1.42 | 1.34 | |
| Research And Ddevelopement To Revenue | 0.21 | 0.20 | |
| Capex To Revenue | (0.13) | (0.13) | |
| Revenue Per Share | 0.67 | 0.64 | |
| Ebit Per Revenue | (0.18) | (0.18) |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Rigel Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Additional Information and Resources on Investing in Rigel Stock
When determining whether Rigel Pharmaceuticals is a strong investment it is important to analyze Rigel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rigel Pharmaceuticals' future performance. For an informed investment choice regarding Rigel Stock, refer to the following important reports:Check out Rigel Pharmaceuticals Piotroski F Score and Rigel Pharmaceuticals Altman Z Score analysis. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.48) | Earnings Share (0.11) | Revenue Per Share 0.684 | Quarterly Revenue Growth 0.133 | Return On Assets (0.08) |
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.